This is compared with funding of $859 million for HIV vaccine-related research and development in the same year: 3.5-times more than microbicides. [119] A successful product will require extensive ...

Empiric studies of breakthrough infections following prophylactic use of ARV-based microbicides that monitor disease progression, viral evolution and resistance patterns are urgently needed for ...